Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population

The metabolic syndrome is a constellation of epidemics, involving type 2 diabetes mellitus (T2DM), hypertension, hyperlipidemia, and obesity, that share common biological and societal pathways.[1 –4] This pathological metabolic milieu collectively increases the individual’s risk of cardiovascular diseases, including coronary heart disease and heart failure.[3,5,6] More recently, metabolic dysfunction-associated steatotic liver disease (MASLD) has been increasingly recognized as a key man ifestation of this systemic metabolic disease.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research